Page 88 - The clinical aspects and management of chronic migraine Judith Anne Pijpers

86
Chapter 4
40. Deen M, Martinelli D, Pijpers J, et al. Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia. 2019;39(8):1058- 1066. doi:10.1177/0333102419847751
41. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. Neurology. 2018;0:10.1212/WNL.0000000000006640. doi:10.1212/WNL.0000000000006640
42. Louter MA, Bosker JE, van Oosterhout WPJ, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(11):3489-3496. doi:10.1093/brain/awt251
43. Rossi P, Jensen R, Nappi G, Allena M. A narrative review on the management of medication overuse headache: The steep road from experience to evidence. J Headache Pain. 2009;10(6):407-417. doi:10.1007/s10194-009-0159-6
44. NICE guidance TA260. Botulinum to toxin xin type A for the pre prev vention of headaches in adults with chronic migraine. 2012;TA260(June 2012).
45. Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91. doi:10.1186/s10194-018-0921-8
46. Ostelo RWJG, Deyo RA, Stratford P, et al. Interpreting Change Scores for Pain and Functional Status in Low Back Pain. Spine (Phila Pa 1976). 2008;33(1):90-94. doi:10.1097/BRS.0b013e31815e3a10
47. Herd C, Tomlinson C, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Chochrane Syst Rev. 2018;(6). doi:10.1002/14651858.CD011616.pub2.www.cochranelibrary.com
48. Louter M, Wardenaar K, Veen G, et al. Allodynia is associated with a higher prevalence of depression in migraine patients. Cephalalgia. 2014;34(14)